|
|
 |
|
Viewing report
|
|
|
|
Bipolar Disorder- Drug Pipeline Analysis and Market Forecasts to 2015
GlobalData, Dec 2009, Pages: 53
“Bipolar Disorder – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global bipolar disorder market. The report identifies the key trends shaping and driving the dynamism in the global bipolar disorder market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global bipolar disorder sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
Scope
The scope of the report includes:
- Annualized global bipolar disorder market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include dopamine serotonin receptor targettors, immunotherapy, enzyme inhibitors, serotonin receptor modulators, acetylcholine inhibitors, muscarinic antagonists, combinational therapy, ion channel modulators, dopamine agonist/antagonist and kappa opiod agonists.
- Analysis of the current and future market competition in the global bipolar disorder market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
- Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the bipolar disorder therapeutics market in the long run. Key future market players covered are are Johnson & Johnson, Dainippon Sumitomo, Lundebeck, Alexza and Repligen
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with bipolar disorder.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bipolar disorder market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global bipolar disorder market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global bipolar disorder market landscape? – Identify, understand and capitalize.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Bipolar Disorder - Global Strategic Business Report
The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Bipolar Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
The Central Nervous Systems Market 2010 Report
The Neurotechnology Industry 2011 Report
Bipolar Depression - Pipeline Review, Q1 2011
Drug Delivery Technology - Revolutionizing CNS Therapies
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
|
|
|
|
